Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Randomised controlled trials (RCTs) indicate that statin therapy has cardiovascular benefit among patients with type 2 diabetes. Recently, statins were reported to increase risk of diabetes by 9%. The aim was to investigate by a meta-analysis whether statins deteriorate glycaemic control in type 2 diabetes. METHODS: Medline, EMBASE and Cochrane Central Register of Controlled Trials from 1966 to 2012 were searched for RCTs of statins. Included were only trials with type 2 diabetes. MAIN OUTCOME MEASURES: The I(2) statistic was used to measure heterogeneity between trials and calculated mean differences for glycaemic parameters with random-effect meta-analysis. RESULTS: 26 eligible studies were identified with 3232 participants. Statin therapy had no remarkable influence on HbA1c (WMD 0.04%, 95% CI -0.08 to 0.16, I² = 45.7%, n = 3070), FPG (2.25 mg/dl, 95% CI -3.50 to 7.99, I² = 46%, n = 1176), BMI, fasting insulin or HOMA-IR. However, subgroup analysis showed significant, detrimental effect of atorvastatin on HbA1c, whereas simvastatin presented an ameliorative effect. Meta-regression presented that neither baseline age nor relative reduction in LDL-cholesterol concentrations accounted for residual heterogeneity. CONCLUSION: Statin therapy showed non-significant effect on glycaemic control in type 2 diabetes. Statin therapy need not change among them with moderate or high cardiovascular risk or existing cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · cited 2×
“Randomised controlled trials (RCTs) indicate that statin therapy has cardiovascular benefit among patients with type 2 diabetes, and clinical guidelines recommend prescription of statins in such patients irrespective of baseline serum cholesterol levels [2,4-6].”
BackgroundPreiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12475-0 · Cited by 492
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
Waters, D. D., Ho, J. E., DeMicco, D. A., Breazna, A., Arsenault, B. J., Wun, C.-C., Kastelein, J. J., Colhoun, H., & Barter, P. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.047 · Cited by 333 · cited 1×
“compared with placebo in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was even associated with a 44% increased risk of new-onset diabetes [9].”
The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia
The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1335 · Cited by 128
Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients
Sukhija, R., Prayaga, S., Marashdeh, M., Bursac, Z., Kakar, P., Bansal, D., Sachdeva, R., Kesan, S. H., & Mehta, J. L. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318197ec8b · Cited by 126
Cited by
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119
Barrios, V., Escobar, C., Cicero, A. F. G., Burke, D., Fasching, P., Banach, M., & Bruckert, E. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.003 · Cited by 96
“Ezetimibe has been shown to improve insulin resistance [66], whereas statins, on the contrary, do not [67].”
Statins and risk of type 2 diabetes: mechanism and clinical implications
Laakso, M., & Fernandes Silva, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1239335 · Cited by 82
Type 2 diabetes and cardiovascular disease: what next?
Joseph, J. J., & Golden, S. H. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000044 · Cited by 57
Metadata
- Authors
- Zhou, Y., Yuan, Y., Cai, R.-R., Huang, Y., Xia, W.-Q., Yang, Y., Wang, P., Wei, Q., & Wang, S.-H.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2013-07-05
- Volume
- 14
- Issue
- 12
- Pages
- 1575-1584
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2128841850
- Cited by
- 33
- References
- 9
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. https://app.cochat.ai/papers/10.1517/14656566.2013.810210
- The paper
- Zhou, Y., Yuan, Y., Cai, R.-R., Huang, Y., Xia, W.-Q., Yang, Y., Wang, P., Wei, Q., & Wang, S.-H. (2013). Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2013.810210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.